Welcome to our dedicated page for Io Biotech SEC filings (Ticker: IOBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IO Biotech SEC filings document the company's transition from a Nasdaq-listed clinical-stage biopharmaceutical issuer to a Chapter 7 bankruptcy case after ceasing operations. The filings record trustee control over assets and liabilities, liquidation proceedings, related debt-default matters, and the limited recovery expectations disclosed for common stockholders.
Earlier filings cover quarterly operating updates, investor presentation materials, Nasdaq continued-listing compliance, workforce-reduction and exit-cost disclosures, officer and principal accounting officer changes, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory updates tied to the company's T-win cancer vaccine programs.
IO Biotech disclosed topline results from its Phase 3 IOB-013 study evaluating Cylembio plus pembrolizumab versus pembrolizumab alone as first-line treatment for unresectable or metastatic melanoma. The randomized trial enrolled 407 patients (203 combination, 204 monotherapy). The primary endpoint, progression-free survival assessed by blinded independent review per RECIST v1.1, showed early and sustained separation with a hazard ratio (HR) of 0.77 (95% CI: 0.58–1.00; p=0.056), and median PFS of 19.4 months versus 11.0 months. The primary result falls short of the prespecified significance threshold.
Notable subgroup findings include a pronounced benefit in PD-L1 negative tumors (HR 0.54; mPFS 16.6 vs 3.0 months; nominal p=0.006) and in patients without prior anti–PD-1 therapy (post hoc HR 0.74; mPFS 24.8 vs 11.0 months; nominal p=0.037). Overall survival trends were favorable but immature (HR 0.79; 95% CI: 0.57–1.10). The combination was generally well tolerated; injection site reactions were most common (reported in 56% of combination arm patients) and resolved on treatment. The company plans regulatory discussions about a potential BLA and will present more detailed data. It disclosed an estimated cash balance of approximately $28.1 million plus a €12.5 million tranche drawn under a term loan, which it expects to fund operations into the first quarter of 2026, subject to final close procedures.
IO Biotech (Nasdaq: IOBT) filed an 8-K announcing that it has met the conditions to draw the €12.5 million Tranche B of its previously disclosed €57.5 million term-loan facility with the European Investment Bank (EIB).
In exchange, the EIB received a warrant to purchase up to 4,221,867 shares of common stock at a strike price of $1.3159. The drawdown is expected on or about July 4, 2025.
- The warrant and the underlying shares were issued in a private placement relying on Section 4(a)(2).
- Key warrant terms are unchanged from the December 20 2024 filing.
The transaction bolsters near-term liquidity but introduces potential dilution for existing shareholders.
IO Biotech, Inc. (Nasdaq: IOBT) filed a Form 8-K to disclose an Addendum to the 2017 service agreement with Chief Executive Officer Mai-Britt Zocca, Ph.D. The addendum, executed 19 June 2025 by subsidiary IO Biotech ApS, formalises severance and change-in-control protections.
Standard Qualifying Termination (without cause or by the CEO for good reason) entitles the CEO to:
- Cash severance equal to 12 months of current base salary.
- Pro-rated annual bonus for the year of termination, calculated on actual performance.
- Any unpaid prior-year bonus.
- Accelerated vesting of equity awards scheduled to vest within 12 months after termination, with performance awards vesting on actual results.
Change-in-Control (CIC) Protection: If a Qualifying Termination occurs within six months before or 12 months after a CIC, (i) cash severance increases to 18 months of base salary, (ii) the current-year bonus is paid at full, non-prorated value, and (iii) 100 % of outstanding equity vests immediately, with performance goals deemed met at target or as otherwise specified in award agreements.
All payments are contingent on execution and non-revocation of a general release of claims. The company attached the Addendum as Exhibit 10.1; no other financial statements or exhibits were included.
The disclosure does not alter current operations or financial guidance but increases potential cash outflows and equity dilution in a termination or CIC scenario. Investors should note the enhanced protection may aid retention during strategic discussions but could represent a modest cost if triggered.